Preeclampsia Market Expected to Reach USD 116 million by 2034

The Preeclampsia Market Size in the seven major markets (7MM) is expected to grow from USD 87 million in 2025 to USD 116 million by 2034, reflecting a CAGR of 3.30%. This growth is primarily driven by increasing awareness, advancements in diagnostic technologies, and evolving maternal healthcare systems in leading countries such as the United States, EU4, the United Kingdom, and Japan. Among these, the United States accounted for the largest market share, approximately USD 70 million in 2024.

Preeclampsia is a complex pregnancy disorder characterized by new-onset hypertension and proteinuria after 20 weeks of gestation. It is believed to stem from placental dysfunction, leading to systemic endothelial activation and inflammatory responses that affect maternal circulation. Preeclampsia is more prevalent in first-time mothers, women with a family history of the condition, and those with preexisting health issues such as hypertension or diabetes.

Diagnosis of preeclampsia is based on routine prenatal screenings measuring blood pressure and urine protein, confirmed with readings of ≥140/90 mmHg and proteinuria ≥300 mg in a 24-hour urine collection. In May 2023, Thermo Fisher Scientific received FDA clearance for two assays that assess preeclampsia risk by measuring PIGF and sFlt-1 levels. These assays, the first to receive breakthrough designation, run in 30 minutes on the BRAHMS KRYPTOR analyzer and can help evaluate the risk of developing severe preeclampsia in hospitalized pregnant individuals within the next two weeks.

The differential diagnosis of preeclampsia includes antiphospholipid antibody syndrome, thrombotic microangiopathies, lupus nephritis, epilepsy or seizure disorder, chronic renal disease, chronic liver disease, gestational hypertension, and chronic hypertension. According to DelveInsight’s estimates, the total diagnosed incidence cases of preeclampsia in the 7MM were found to be approximately 334,000 in 2024. Within the 7MM, the United States accounted for the highest incidence of preeclampsia in 2024, with around 218,000 cases.

Currently, there are no approved therapies for preeclampsia; delivery remains the only cure, and management primarily relies on antihypertensive agents, anticonvulsants, and corticosteroids. The emerging treatment landscape for preeclampsia is not very active, with only a few companies conducting research, most of which are in preclinical stages. Recently, Comanche Biopharma’s CBP-4888 has gained attention after receiving Fast Track Designation (FTD) for preeclampsia, marking a promising development in this underserved area.

DelveInsight’s “Preeclampsia – Market Insight, Epidemiology, and Market Forecast – 2034” report offers a comprehensive analysis of the epidemiology, market dynamics, and clinical development landscape of Preeclampsia. In addition, the report presents historical and forecasted epidemiological and market data, along with an in-depth assessment of therapeutic market trends across the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

The Preeclampsia Market Report highlights current treatment practices, emerging therapies, and the market share of individual drugs while providing detailed insights into the current and projected Preeclampsia market size across the 7MM from 2020 to 2034. Furthermore, it examines existing treatment approaches and unmet medical needs to identify key growth opportunities and evaluate the overall market potential.

Preeclampsia Disease Understanding

Hypertensive disorders during pregnancy remain one of the primary causes of maternal and perinatal mortality worldwide. Preeclampsia, with or without severe features, is a pregnancy-related condition characterized by new-onset hypertension, often accompanied by proteinuria, that typically occurs after 20 weeks of gestation and most commonly near term. The condition represents a continuum of hypertensive disease in pregnancy—beginning as gestational hypertension and potentially progressing to more severe forms such as eclampsia and HELLP syndrome (hemolysis, elevated liver enzymes, and low platelet count). Early diagnosis and timely management are critical to preventing both maternal and neonatal complications, primarily through symptom control and planned delivery.

Learn about disease understanding, clinical developments, and unmet needs shaping the future of maternal health: Get an In-Depth Preeclampsia Overview

Preeclampsia Diagnosis

Diagnosis of preeclampsia is based on the detection of hypertension—defined as a systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg—after 20 weeks of gestation, along with proteinuria (≥300 mg in a 24-hour urine collection or a protein-to-creatinine ratio ≥0.3). In cases without proteinuria, the diagnosis can still be established if there are indicators of organ dysfunction such as renal impairment (creatinine >1.1 mg/dL), elevated liver enzymes, neurological symptoms (e.g., headaches or visual disturbances), or thrombocytopenia. Severe preeclampsia is identified by markedly elevated blood pressure (≥160/110 mmHg), substantial proteinuria, or complications including pulmonary edema and organ damage.

Preeclampsia Treatment

To manage elevated blood pressure, medications such as labetalol, nifedipine, or methyldopa may be used. Labetalol is specifically approved for use during pregnancy, while the others are used off-label when the potential benefits outweigh the risks. In severe cases, anticonvulsant therapy may be administered to prevent or control seizures. Delivery is generally recommended between 37 and 38 weeks of gestation, either through induced labor or cesarean section, to reduce the risk of complications. If the condition deteriorates before 37 weeks, earlier delivery may be required, although this can increase the risk of premature birth complications for the baby.

After delivery, preeclampsia typically resolves; however, complications can still occur in the days following birth. Blood pressure monitoring continues postpartum, and additional antihypertensive therapy may be prescribed if necessary. Newborns delivered prematurely may need care in a neonatal intensive care unit (NICU). Postpartum follow-up appointments are essential to monitor blood pressure and determine if ongoing treatment is needed.

Preeclampsia Epidemiology

The Preeclampsia epidemiology chapter of the report presents both historical and forecasted data, segmented by total incidence cases, diagnosed incidence cases, age-specific cases, subtype-specific cases, severity-specific cases, and treated cases of Preeclampsia across the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan for the period 2020–2034.

Gain access to detailed incidence, diagnosis, and treatment trends across major markets: Dive Deep into the Preeclampsia Epidemiology 

Preeclampsia Epidemiology Segmentation

The Preeclampsia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Preeclampsia Incidence Cases
• Preeclampsia Diagnosed Incidence Cases
• Preeclampsia Age-specific Cases
• Preeclampsia Sub-type Specific Cases
• Preeclampsia Treated Cases

Recent Development In The Preeclampsia Treatment Landscape:

• In Feb 2025, Roche announced that its Elecsys® sFlt-1/PlGF ratio test for preeclampsia received 510(k) clearance from the U.S. FDA. The prognostic test helps stratify hospitalized pregnant women with hypertensive disorders of pregnancy into low- and high-risk groups for developing severe preeclampsia within two weeks. This advancement aims to improve prediction, enable early intervention, and reduce adverse maternal and fetal outcomes. Preeclampsia cases in the U.S. have risen by 25% over the past two decades, with Black women facing disproportionately higher risks and complications.

Preeclampsia Key Companies:

• Diabetomics, Inc.
• Metabolomic Diagnostics Ltd.
• Sera Prognostics
• Thermo Fisher Scientific Inc.
• Siemens Healthineers AG
• Bayer AG, and others.

Understand market dynamics, key players, and future growth opportunities shaping the 7MM landscape: Explore Comprehensive Insights into the Preeclampsia Market 

Preeclampsia Market Drivers:

• Rising incidence of preeclampsia across major markets
• Advancements in diagnostic technologies (PlGF/sFlt-1 assays)
• Increasing R&D in targeted and disease-modifying therapies
• Growing awareness and improved prenatal screening programs
• Supportive regulatory designations (Fast Track, Orphan Drug, Breakthrough)

Preeclampsia Market Barriers:

• Absence of approved disease-modifying therapies
• Limited diagnostic access in low-resource settings
• Complex and poorly understood disease pathophysiology
• High cost and slow adoption of advanced diagnostics
• Sparse therapeutic pipeline and low industry investment

Scope of the Preeclampsia Market Report

• Study Period: 2020–2034
• Coverage: 7MM [United States, Japan, EU4 & UK]
• Key Preeclampsia Companies: Diabetomics, Inc., Metabolomic Diagnostics Ltd., Sera Prognostics, Thermo Fisher Scientific Inc., Siemens Healthineers AG, Bayer AG, and others.

Analyze market forecasts, evolving therapies, and diagnostic advancements driving innovation through 2034: Uncover the Latest Preeclampsia Market Outlook